本文關(guān)鍵詞： 藥效持續(xù)時(shí)間 慢性阻塞性肺病 氣流阻塞 慢性支氣管炎 FDA 呼吸困難 吸入氣霧劑 藥品審評(píng) 致死病因 激動(dòng)劑 　出處：《中國(guó)藥學(xué)雜志》2014年18期 　論文類型：期刊論文

【摘要】：正近日,FDA批準(zhǔn)Striverdi Respimat(olodaterol)吸入氣霧劑用于治療慢性阻塞性肺病(COPD),包括出現(xiàn)氣流阻塞的慢性支氣管炎和/或肺氣腫。Striverdi Respimat藥效持續(xù)時(shí)間較長(zhǎng),每日給藥一次。COPD是一種能夠引起呼吸困難的嚴(yán)重肺部疾病,會(huì)隨時(shí)間推移而惡化。其癥狀包括氣喘、咳嗽、胸悶和氣短。吸煙是引
[Abstract]:The FDA has recently approved the use of Striverdi Respimatatine olodaterol) inhaled aerosols for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema with chronic bronchitis and / or emphysema for a longer period of time. Once a day. COPD is a severe lung disease that can cause dyspnea, which can worsen over time. Symptoms include asthma, cough, chest tightness and shortness of breath.
【分類號(hào)】：R563.9
，

本文編號(hào)：1520907